Asarina has completed the recruitment of patients to its phase 2a clinical study in Tourette syndrome with a total of 28 patients enrolled.
A new study by the U.S. CDC (Centers for Disease Control and Prevention) estimates that 1-in-50 children in the US may be affected by Tourette or persistent tic disorders, previous estimates were 1-in-100, and that up to 450,000 U.S. children and adults have Tourette. Asarina Pharma is currently carrying out a phase IIa clinical study into Sepranolone, an endogenous neurohormonal treatment for Tourette that aims to reduce tics with no significant side effects.